Replidyne Completes Phase 2 Enrollment
Louisville, Colorado-based Replidyne said today that it has completed enrollment for a Phase 2 trial evaluating the firm's treatment for infections of the middle ear. The firm said that the study will include 300 children, and will be complete by the first quarter of 2007. Replidyne is commercializing faropenem medoxomil (faropenem), a treatment for pediatric patients with acute otitis media infections of the middle ear.
posted on Wednesday, December 20, 2006
Related companies:
Replidyne
Related stories:
> Myriad Completes Phase 3 Trial Enrollment
> Replidyne to Merge with Cardiovascular Systems
> Replidyne Appoints VPs
> Replidyne Sets IPO Pricing
> TeleTech Snags Client
Techrockies.com Home